Xicheng Wang

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University, Peking Union Medical College Hospital, Peking University Cancer Hospital, First Affiliated Hospital of Guangdong Pharmaceutical University · ORCID：0000-0001-6073-2869

发表论文 16 篇 · 总被引 231 次 · h-index 8

代表论文

• Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials (2024 · Journal of Clinical Oncology · 被引 50)
• Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial (2024 · The Lancet Respiratory Medicine · 被引 42)
• Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019 (2020 · Chinese Journal of Cancer Research · 被引 25)
• Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer (2024 · Cancer Cell · 被引 22)
• PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial (2025 · Signal Transduction and Targeted Therapy · 被引 13)
• Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial. (2024 · Journal of Clinical Oncology · 被引 12)